We report detailed functional analyses and genotype-phenotype correlations in 392 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel Nav1.6, with the aim of describing clinical phenotypes related to functional effects. Six different clinical subgroups were identified: Group 1, benign familial infantile epilepsy (n = 15, normal cognition, treatable seizures); Group 2, intermediate epilepsy (n = 33, mild intellectual disability, partially pharmaco-responsive); Group 3, developmental and epileptic encephalopathy (n = 177, severe intellectual disability, majority pharmaco-resistant); Group 4, generalized epilepsy (n = 20, mild to moderate intellectual disability, frequently with absence seizures); Group 5, unclassifiable epilepsy (n = 127); and Group 6, neurodevelopmental disorder without epilepsy (n = 20, mild to moderate intellectual disability). Those in Groups 1-3 presented with focal or multifocal seizures (median age of onset: 4 months) and focal epileptiform discharges, whereas the onset of seizures in patients with generalized epilepsy was later (median: 42 months) with generalized epileptiform discharges. We performed functional studies expressing missense variants in ND7/23 neuroblastoma cells and primary neuronal cultures using recombinant tetrodotoxin-insensitive human Nav1.6 channels and whole-cell patch-clamping. Two variants causing developmental and epileptic encephalopathy showed a strong gain-of-function (hyperpolarizing shift of steady-state activation, strongly increased neuronal firing rate) and one variant causing benign familial infantile epilepsy or intermediate epilepsy showed a mild gain-of-function (defective fast inactivation, less increased firing). In contrast, all three variants causing generalized epilepsy induced a loss-of-function (reduced current amplitudes, depolarizing shift of steady-state activation, reduced neuronal firing). Functional effects were known for 170 individuals. All 136 individuals carrying a functionally tested gain-of-function variant had either focal (n = 97, Groups 1-3) or unclassifiable (n = 39) epilepsy, whereas 34 individuals with a loss-of-function variant had either generalized (n = 14), no (n = 11) or unclassifiable (n = 6) epilepsy; only three had developmental and epileptic encephalopathy. Computational modelling in the gain-of-function group revealed a significant correlation between the severity of the electrophysiological and clinical phenotypes. Gain-of-function variant carriers responded significantly better to sodium channel blockers than to other anti-seizure medications, and the same applied for all individuals in Groups 1-3. In conclusion, our data reveal clear genotype-phenotype correlations between age at seizure onset, type of epilepsy and gain- or loss-of-function effects of SCN8A variants. Generalized epilepsy with absence seizures is the main epilepsy phenotype of loss-of-function variant carriers and the extent of the electrophysiological dysfunction of the gain-of-function variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Our pharmacological data indicate that sodium channel blockers present a treatment option in SCN8A-related focal epilepsy with onset in the first year of life.

Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications / K.M. Johannesen, Y. Liu, M. Koko, C.E. Gjerulfsen, L. Sonnenberg, J. Schubert, C.D. Fenger, A. Eltokhi, M. Rannap, N.A. Koch, S. Lauxmann, J. Krüger, J. Kegele, L. Canafoglia, S. Franceschetti, T. Mayer, J. Rebstock, P. Zacher, S. Ruf, M. Alber, K. Sterbova, P. Lassuthová, M. Vlckova, J.R. Lemke, K. Platzer, I. Krey, C. Heine, D. Wieczorek, J. Kroell-Seger, C. Lund, K.M. Klein, P.Y.B. Au, J.M. Rho, A.W. Ho, S. Masnada, P. Veggiotti, L. Giordano, P. Accorsi, C.E. Hoei-Hansen, P. Striano, F. Zara, H. Verhelst, J.S. Verhoeven, H.M.H. Braakman, B. van der Zwaag, A.V.E. Harder, E. Brilstra, M. Pendziwiat, S. Lebon, M. Vaccarezza, N.M. Le, J. Christensen, S. Grønborg, S.W. Scherer, J. Howe, W. Fazeli, K.B. Howell, R. Leventer, C. Stutterd, S. Walsh, M. Gerard, B. Gerard, S. Matricardi, C.M. Bonardi, S. Sartori, A. Berger, D. Hoffman-Zacharska, M. Mastrangelo, F. Darra, A. Vøllo, M.M. Motazacker, P. Lakeman, M. Nizon, C. Betzler, C. Altuzarra, R. Caume, A. Roubertie, P. Gélisse, C. Marini, R. Guerrini, F. Bilan, D. Tibussek, M. Koch-Hogrebe, M.S. Perry, S. Ichikawa, E. Dadali, A. Sharkov, I. Mishina, M. Abramov, I. Kanivets, S. Korostelev, S. Kutsev, K.E. Wain, N. Eisenhauer, M. Wagner, J.M. Savatt, K. Müller-Schlüter, H. Bassan, A. Borovikov, M.C. Nassogne, A. Destrée, A.S. Schoonjans, M. Meuwissen, M. Buzatu, A. Jansen, E. Scalais, S. Srivastava, W.H. Tan, H.E. Olson, T. Loddenkemper, A. Poduri, K.L. Helbig, I. Helbig, M.P. Fitzgerald, E.M. Goldberg, T. Roser, I. Borggraefe, T. Brünger, P. May, D. Lal, D. Lederer, G. Rubboli, H.O. Heyne, G. Lesca, U.B.S. Hedrich, J. Benda, E. Gardella, H. Lerche, R.S. Møller. - In: BRAIN. - ISSN 1460-2156. - 145:9(2022 Sep 14), pp. 2991-3009. [10.1093/brain/awab321]

Genotype-phenotype correlations in SCN8A-related disorders reveal prognostic and therapeutic implications

P. Veggiotti;S. Sartori;
2022

Abstract

We report detailed functional analyses and genotype-phenotype correlations in 392 individuals carrying disease-causing variants in SCN8A, encoding the voltage-gated Na+ channel Nav1.6, with the aim of describing clinical phenotypes related to functional effects. Six different clinical subgroups were identified: Group 1, benign familial infantile epilepsy (n = 15, normal cognition, treatable seizures); Group 2, intermediate epilepsy (n = 33, mild intellectual disability, partially pharmaco-responsive); Group 3, developmental and epileptic encephalopathy (n = 177, severe intellectual disability, majority pharmaco-resistant); Group 4, generalized epilepsy (n = 20, mild to moderate intellectual disability, frequently with absence seizures); Group 5, unclassifiable epilepsy (n = 127); and Group 6, neurodevelopmental disorder without epilepsy (n = 20, mild to moderate intellectual disability). Those in Groups 1-3 presented with focal or multifocal seizures (median age of onset: 4 months) and focal epileptiform discharges, whereas the onset of seizures in patients with generalized epilepsy was later (median: 42 months) with generalized epileptiform discharges. We performed functional studies expressing missense variants in ND7/23 neuroblastoma cells and primary neuronal cultures using recombinant tetrodotoxin-insensitive human Nav1.6 channels and whole-cell patch-clamping. Two variants causing developmental and epileptic encephalopathy showed a strong gain-of-function (hyperpolarizing shift of steady-state activation, strongly increased neuronal firing rate) and one variant causing benign familial infantile epilepsy or intermediate epilepsy showed a mild gain-of-function (defective fast inactivation, less increased firing). In contrast, all three variants causing generalized epilepsy induced a loss-of-function (reduced current amplitudes, depolarizing shift of steady-state activation, reduced neuronal firing). Functional effects were known for 170 individuals. All 136 individuals carrying a functionally tested gain-of-function variant had either focal (n = 97, Groups 1-3) or unclassifiable (n = 39) epilepsy, whereas 34 individuals with a loss-of-function variant had either generalized (n = 14), no (n = 11) or unclassifiable (n = 6) epilepsy; only three had developmental and epileptic encephalopathy. Computational modelling in the gain-of-function group revealed a significant correlation between the severity of the electrophysiological and clinical phenotypes. Gain-of-function variant carriers responded significantly better to sodium channel blockers than to other anti-seizure medications, and the same applied for all individuals in Groups 1-3. In conclusion, our data reveal clear genotype-phenotype correlations between age at seizure onset, type of epilepsy and gain- or loss-of-function effects of SCN8A variants. Generalized epilepsy with absence seizures is the main epilepsy phenotype of loss-of-function variant carriers and the extent of the electrophysiological dysfunction of the gain-of-function variants is a main determinant of the severity of the clinical phenotype in focal epilepsies. Our pharmacological data indicate that sodium channel blockers present a treatment option in SCN8A-related focal epilepsy with onset in the first year of life.
SCN8A; epilepsy; genetics; personalized medicine
Settore MED/39 - Neuropsichiatria Infantile
Article (author)
File in questo prodotto:
File Dimensione Formato  
SCN8A.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 3.21 MB
Formato Adobe PDF
3.21 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
awab321_compressed.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 389.76 kB
Formato Adobe PDF
389.76 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/949883
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 18
social impact